Ahmed M. Elamir
Assistant professor (tenure track)
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Ahmed M. Elamir is an Assistant Professor (tenure track) at East Carolina University in the United States. His primary research areas focus on the intersection of radiation therapy and immunology, particularly in the context of pancreatic cancer. Dr. Elamir's recent work highlights how presurgical ablative radiation can enhance local control and immune responses in patients with this challenging disease.
Articles (2)
Purpose: To compare outcomes and molecular characteristics of patients who had surgery after neoadjuvant (NA) chemotherapy, with and without stereotactic ablative radiotherapy (SAbR), for pancreatic cancer. Insight could clarify the benefits of SAbR and provide molecular guidance for future therapeutic regimens. Experimental Design: This single-institution, tertiary care academic center cohort study included all patients diagnosed with pancreatic cancer between 2012 and 2023 treated with NA chemotherapy, with or without SAbR. We compared therapeutic responses, performed patient matching, and conducted Cox modeling to identify differences between groups. We assessed molecular response using RNA sequencing to identify SAbR-induced biologic differences. Results: Among 133 patients receiving chemotherapy and 48 receiving chemotherapy + SAbR, RNA sequencing was available for 29 and 14 patients, respectively. Despite more advanced baseline disease, the SAbR group showed better posttreatment pathology and similar overall survival [HR = 0.97, 95% confidence interval (CI), 0.58–1.60, P = 0.9]. Patient matching indicated that SAbR improved locoregional recurrence-free survival (HR = 0.24, 95% CI, 0.07–0.88, P = 0.009). Arterial involvement raised local failure risk with chemotherapy alone (HR = 3.37, 95% CI, 1.74–6.54, P < 0.001), which was significantly reduced with SAbR (HR = 0.28; 95% CI, 0.12–0.68; P = 0.005). Gene set enrichment analysis showed immune activation, with CD8 and NK/NKT cell signatures associated with local control and Treg signatures associated with worse control. Conclusions: NA SAbR is associated with improved pathologic outcomes, enhanced local control, and maintained survival while inducing a distinct immune response. Well-powered studies are needed to clarify its clinical benefits.
Year:
2025
Purpose: To compare outcomes and molecular characteristics of patients who had surgery after neoadjuvant (NA) chemotherapy, with and without stereotactic ablative radiotherapy (SAbR), for pancreatic cancer. Insight could clarify the benefits of SAbR and provide molecular guidance for future therapeutic regimens. Experimental Design: This single-institution, tertiary care academic center cohort study included all patients diagnosed with pancreatic cancer between 2012 and 2023 treated with NA chemotherapy, with or without SAbR. We compared therapeutic responses, performed patient matching, and conducted Cox modeling to identify differences between groups. We assessed molecular response using RNA sequencing to identify SAbR-induced biologic differences. Results: Among 133 patients receiving chemotherapy and 48 receiving chemotherapy + SAbR, RNA sequencing was available for 29 and 14 patients, respectively. Despite more advanced baseline disease, the SAbR group showed better posttreatment pathology and similar overall survival [HR = 0.97, 95% confidence interval (CI), 0.58–1.60, P = 0.9]. Patient matching indicated that SAbR improved locoregional recurrence-free survival (HR = 0.24, 95% CI, 0.07–0.88, P = 0.009). Arterial involvement raised local failure risk with chemotherapy alone (HR = 3.37, 95% CI, 1.74–6.54, P P = 0.005). Gene set enrichment analysis showed immune activation, with CD8 and NK/NKT cell signatures associated with local control and Treg signatures associated with worse control. Conclusions: NA SAbR is associated with improved pathologic outcomes, enhanced local control, and maintained survival while inducing a distinct immune response. Well-powered studies are needed to clarify its clinical benefits.
Year:
2025
Collaborators (12)
Zhikai Chi
University of Texas Southwestern Medical Center
Cheryl Lewis
Associate Professor
University of Texas Southwestern
Todd Aguilera
University of Texas Southwestern Medical Center
John Mansour
Professor
University of Texas Southwestern Medical Center
Adam Yopp
Professor of Surgery
University of Texas Southwestern Medical Center
Song Zhang
-
Matthew R. Porembka
University of Texas Southwestern Medical Center
David Hsiehchen
University of Texas Southwestern Medical Center
Syed Kazmi
Assistant Professor
University of Texas Southwestern Medical Center
Patricio M. Polanco
Professor
-
Herbert Zeh
Chair of Surgery
University of Texas Southwestern Medical Center
Nina N Sanford
University of Texas Southwestern
Make your next move.
Prepare your application
Review drafts before you send them.